Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Clinical trial transparency stories

Nov 20, 2026

FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time

The FDA declined to approve Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy, citing significant issues with trial data reliability. This is the second rejection for the treatment, dealing a major blow to the company.

Nov 20, 2026·4 sources
00

Top claims

  • ▪A group of 28 physicians and researchers involved in deramiocel development sent a letter to senior FDA leadership in October 2026 advocating for the drug's approval
  • ▪Capricor's original deramiocel approval application was denied in July 2025 after the FDA found it lacked substantial evidence of effectiveness
  • ▪Deramiocel was designed to protect muscle tissue that Duchenne muscular dystrophy progressively destroys, distinguishing it from other approved drugs that slow the condition or address its genetic mutations

Subtopics

Clinical trial design1Corporate layoffs1Drug Policy, Pricing & Approval1FDA drug approval1Genetic diseases1Rare diseases1Stock market performance1

Related timelines

Congress

110 stories

Trump administration

161 stories

Crypto hacks

100 stories

Russia-Ukraine war

136 stories

US midterm elections

102 stories